About siRNAgen Therapeutics

The startup develops a gene interference technology utilizing a proprietary RNA interference (RNAi) platform to achieve precise cellular targeting and effective reduction of disease-causing proteins. This technology specifically addresses the challenges of RNAi delivery in treating immunological and fibrotic diseases, enabling more effective therapies for chronic conditions.

```xml <problem> Current RNA interference (RNAi) delivery methods face challenges in achieving precise cellular targeting and effective reduction of disease-causing proteins, particularly in treating immunological and fibrotic diseases. This limitation hinders the development of effective therapies for chronic conditions. </problem> <solution> siRNAgen Therapeutics is developing a gene interference technology that leverages a proprietary RNAi platform, SAMiRNA, to enhance cellular targeting and improve the reduction of disease-causing proteins. The SAMiRNA platform is designed to overcome the delivery challenges associated with RNAi-based therapeutics, especially in the context of immunological and fibrotic diseases. This technology aims to enable the creation of more effective therapies for various chronic conditions by improving the precision and efficacy of RNAi delivery. </solution> <features> - Proprietary SAMiRNA platform for enhanced RNAi delivery. - Technology designed for precise cellular targeting. - Aims to improve the reduction of disease-causing proteins. - Specifically addresses challenges in treating immunological and fibrotic diseases. </features> <target_audience> The primary target audience includes researchers and pharmaceutical companies focused on developing novel therapies for immunological and fibrotic diseases. </target_audience> ```

What does siRNAgen Therapeutics do?

Where is siRNAgen Therapeutics located?

siRNAgen Therapeutics is based in Cambridge, United Kingdom.

When was siRNAgen Therapeutics founded?

siRNAgen Therapeutics was founded in 2019.

How much funding has siRNAgen Therapeutics raised?

siRNAgen Therapeutics has raised 7500000.

Location

Cambridge, United Kingdom

Founded

2019

Funding

7500000

Employees

6 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

siRNAgen Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

sirnagen.com 300+

Founded 2019 – Cambridge, United Kingdom

Funding

Estimated Funding

$5M+

Team (5+)

No team information available.

Company Description

Problem

Current RNA interference (RNAi) delivery methods face challenges in achieving precise cellular targeting and effective reduction of disease-causing proteins, particularly in treating immunological and fibrotic diseases. This limitation hinders the development of effective therapies for chronic conditions.

Solution

siRNAgen Therapeutics is developing a gene interference technology that leverages a proprietary RNAi platform, SAMiRNA, to enhance cellular targeting and improve the reduction of disease-causing proteins. The SAMiRNA platform is designed to overcome the delivery challenges associated with RNAi-based therapeutics, especially in the context of immunological and fibrotic diseases. This technology aims to enable the creation of more effective therapies for various chronic conditions by improving the precision and efficacy of RNAi delivery.

Features

Proprietary SAMiRNA platform for enhanced RNAi delivery.

Technology designed for precise cellular targeting.

Aims to improve the reduction of disease-causing proteins.

Specifically addresses challenges in treating immunological and fibrotic diseases.

Target Audience

The primary target audience includes researchers and pharmaceutical companies focused on developing novel therapies for immunological and fibrotic diseases.